PI3K/AKT/HIF-1α
Overview
PI3K/AKT/HIF-1α refers to a signaling axis linking phosphoinositide 3-kinase (PI3K), AKT, and hypoxia-inducible factor 1-alpha (HIF-1α). In biomedical research, this pathway is widely recognized as a central regulator of cell survival, metabolism, inflammatory responses, angiogenesis, and adaptation to hypoxic stress. PI3K and AKT are upstream signaling components that can promote HIF-1α stabilization and activity, thereby influencing downstream transcriptional programs involved in glycolysis, oxidative stress responses, and tissue remodeling.
Because of these functions, PI3K/AKT/HIF-1α is frequently studied in cancer, inflammatory disease, neuroinflammation, fibrosis, and metabolic disorders. Recent work has also connected this axis with related pathways such as PI3K/Akt signaling pathway, mTOR, PTEN, SIRT1/HIF-1α pathway, and Nrf-2-SLC7A11-GSH pathway, underscoring its role as an integrative node in disease-associated metabolic reprogramming and stress adaptation.
Recent Publications Summary
Recent studies have examined PI3K/AKT/HIF-1α as a mechanistic node linking hypoxia, glycolytic reprogramming, inflammation, and tissue remodeling across several disease models. In rheumatoid arthritis-associated interstitial lung disease, Glyasperin F was reported to upregulate Sirt1 and suppress PI3K/Akt/HIF-1α signaling, which reduced glycolytic enzymes (HK2, PFK, PKM2, LDHA), lowered lactate and ATP production, and decreased oxidative stress in a murine arthritis-fibrosis model and in TGF-β1/IL-1β-stimulated MRC-5 fibroblasts; HIF-1α overexpression reversed these effects 42216775May. In acute neuroinflammation, radiofrequency electromagnetic fields and pulsed magnetic fields were investigated as neuroprotective interventions in an LPS-induced rat model, with the study specifically proposing attenuation of neuroinflammation and demyelination through PI3K/AKT/HIF-1α-mediated neurovascular protection 42183935May.
The pathway was also implicated in obesity-associated adipose tissue remodeling. Single-nucleus RNA sequencing, spatial transcriptomics, and bulk RNA-seq identified a disease-emergent adipocyte population with an end-of-trajectory signature (hEOS) in obese white adipose tissue, characterized by impaired adipokine secretion and defective insulin signaling; mechanistically, HIF1A activation under hypoxic conditions was associated with increased LAMA4 expression and niche remodeling in coordination with a macrophage subset 42107509May. In sepsis-associated encephalopathy, HIF-1α was shown to impair microglial efferocytosis by interacting with SLC7A11 and suppressing the TAM-Rac1-NCKAP1 axis; pharmacologic inhibition or stabilization of HIF-1α, together with gain- and loss-of-function approaches, was used to define this immunometabolic mechanism in BV2 cells and a CLP mouse model 41990706Apr.
Additional studies linked HIF-1α-centered metabolic signaling to inflammatory and fibrotic disease. Dunhuang Daxiefei Decoction was reported to ameliorate acute lung injury via the HIF-1α/glycolysis/H3K18la axis, consistent with a role for HIF-1α-driven glycolysis in sustaining pro-inflammatory macrophage responses 41903585Mar. In hepatocellular carcinoma, Bie-Jia-Jian Pill was investigated as a means to inhibit tumor glycolysis and promote CD8+ cell-mediated anti-tumor immunity by targeting HIF-1α-PI3K/AKT/mTOR and CCL20, highlighting the pathway’s relevance to cancer immunotherapy and the tumor microenvironment 41866005Mar.
What Changes, What Holds
1. PI3K/AKT/HIF-1α can be therapeutically suppressed to blunt glycolytic fibrosis and oxidative stress, but neuroprotection remains only proposed
NEW DIRECTION Glyasperin F extends the axis beyond its established role as a disease-associated driver by showing that inhibiting PI3K/Akt/HIF-1α can reverse a fibrotic, glycolytic, and oxidative phenotype in rheumatoid arthritis–associated lung disease 42216775May. That fits the baseline’s stress-adaptation framework, but it also suggests the pathway may be a tractable antifibrotic target in this setting. The neuroinflammation study is more tentative: it proposes PI3K/AKT/HIF-1α-mediated neurovascular protection, but does not yet settle mechanism 42183935May.
2. Hypoxia-linked HIF1A activity now appears to remodel adipose niches and to restrain microglial efferocytosis
NEW DIRECTION Obese white adipose tissue is presented as a setting where HIF1A helps define a disease-emergent adipocyte state and niche remodeling, which broadens the baseline beyond survival, metabolism, and angiogenesis into tissue architecture and cell-state emergence 42107509May. Sepsis-associated encephalopathy adds a second, distinct role: HIF-1α is implicated in impaired microglial clearance of apoptotic cells through SLC7A11-linked suppression of the TAM-Rac1-NCKAP1 axis 41990706Apr. These findings do not overturn the overview, but they expand the axis into adipose remodeling and efferocytosis.
3. HIF-1α-centered glycolysis is increasingly framed as a therapeutic lever in inflammatory lung disease and cancer immunity
REINFORCES The acute lung injury study strengthens the established view that HIF-1α drives glycolysis and inflammatory macrophage programs, because benefit tracks with dampening the HIF-1α/glycolysis axis rather than with a new mechanism 41903585Mar. The hepatocellular carcinoma work likewise reinforces the baseline by targeting HIF-1α-PI3K/AKT/mTOR to reduce tumor glycolysis and reshape the tumor microenvironment, which is exactly the kind of downstream transcriptional and metabolic control already attributed to this pathway 41866005Mar.
Overview update candidates: the new adipose-remodeling and microglial-efferocytosis roles for HIF1A; therapeutic suppression of PI3K/Akt/HIF-1α in fibrotic lung disease; HIF-1α/glycolysis as a target in acute lung injury and cancer immunotherapy.
pi3k/akt/hif-1α
Background Contexts
In the literature, the biological baseline, pathological conditions, or disease models commonly surrounding pi3k/akt/hif-1α are described as follows:
- liver tumours (Disease) — 2 papers: PMIDs 41866005, 41819037
- acute lung injury (Disease) — 1 paper: PMIDs 41903585
- C. albicans ATCC 10231 (Organism) — 1 paper: PMIDs 41825727
- Castration-resistant prostate cancer (Disease) — 1 paper: PMIDs 42096738
- CD4+ and CD8+ T cells (Cell Line) — 1 paper: PMIDs 41866005
- diabetic foot ulcer (Disease) — 1 paper: PMIDs 42025984
- Diabetic Peripheral Neuropathy (Disease) — 1 paper: PMIDs 41857368
- immunosuppressive tumor microenvironments (Biological Process) — 1 paper: PMIDs 41866005
- inflammatory conditions (Biological Process) — 1 paper: PMIDs 41819037
- liver cirrhosis (Disease) — 1 paper: PMIDs 41819037
- liver fibrosis severity (Disease) — 1 paper: PMIDs 41819037
- microglial efferocytosis (Biological Process) — 1 paper: PMIDs 41990706
Methodologies & Technologies Used
Researchers utilize the following experimental methods, imaging platforms, computational models, or biological reagents to study pi3k/akt/hif-1α:
- 1-acyl-sn-glycero-3-phosphoserine (Other) — 2 papers: PMIDs 42185524, 42183935
- PC-3 (Cell Line) — 2 papers: PMIDs 42152582, 42096738
- RNA sequencing (Technology) — 2 papers: PMIDs 42107509, 41990706
- Adeno-associated viral (AAV) vectors (Organism) — 1 paper: PMIDs 41857368
- amlexanox (Therapy) — 1 paper: PMIDs 42107509
- Aβ25-35 (Other) — 1 paper: PMIDs 42086126
- bacterial lipopolysaccharide (Other) — 1 paper: PMIDs 41990706
- bleomycin-induced pulmonary fibrosis (Disease) — 1 paper: PMIDs 42216775
- BV2 Murine Microglial Cells (Cell Line) — 1 paper: PMIDs 41990706
- CAMP (Biological Process) — 1 paper: PMIDs 42152582
- cAMP-dependent protein kinase catalytic subunit (Protein) — 1 paper: PMIDs 42152582
- carboxyamidotriazole orotate (Chemical) — 1 paper: PMIDs 42350388
Molecular Interventions & Targets
The primary molecular pathways, regulatory genes, enzymes, or therapeutic agents actively targeted and manipulated in relation to pi3k/akt/hif-1α include:
- glycolytic process (Biological Process) — 2 papers: PMIDs 41903585, 41819037
- alpha-ketoglutaric acid (Chemical) — 1 paper: PMIDs 42350388
- Alzheimer's disease (Disease) — 1 paper: PMIDs 42086126
- angeloylgomisin o (Chemical) — 1 paper: PMIDs 42086126
- Bie-Jia-Jian Pill (Therapy) — 1 paper: PMIDs 41866005
- C-C motif chemokine ligand 20 (Chemical) — 1 paper: PMIDs 41866005
- camptothecin (Chemical) — 1 paper: PMIDs 41819037
- CD44/JAK2/STAT3 signaling pathway (Pathway) — 1 paper: PMIDs 41819037
- Compound OH16 (Chemical) — 1 paper: PMIDs 42096738
- Dihydrolipoyllysine-residue succinyltransferase (Protein) — 1 paper: PMIDs 42350388
- E2F2/PI3K/AKT signaling pathway (Pathway) — 1 paper: PMIDs 41866005
- epigomisin o (Chemical) — 1 paper: PMIDs 42086126
Observed Outcomes & Phenotypes
The phenotypic changes, physiological endpoints, or clinical metrics observed and measured in connection with pi3k/akt/hif-1α include:
- caspase-3 (Protein) — 2 papers: PMIDs 42152582, 42096738
- LDHA (Protein) — 2 papers: PMIDs 42216775, 42152582
- proinflammatory cytokine (Biological Process) — 2 papers: PMIDs 42185524, 42025984
- 2'-deoxyadenosine triphosphate (Biological Process) — 1 paper: PMIDs 42216775
- adenosine triphosphate (Chemical) — 1 paper: PMIDs 42025984
- adipokine (Protein) — 1 paper: PMIDs 42107509
- adiponectin (Protein) — 1 paper: PMIDs 42152582
- AMPKα (Pathway) — 1 paper: PMIDs 42152582
- apoptotic markers (Clinical Metric) — 1 paper: PMIDs 42152582
- AXL (Protein) — 1 paper: PMIDs 41990706
- B-cell lymphoma 2 (Protein) — 1 paper: PMIDs 42152582
- behavioral performance (Clinical Metric) — 1 paper: PMIDs 42086126
General Takeaways & Clinical Potentials
The high-level concepts, clinical translations, and overarching conclusions proposed in the research surrounding pi3k/akt/hif-1α are summarized below:
- ameliorate AD (Other) — 1 paper: PMIDs 42086126
- anti-AD effect (Other) — 1 paper: PMIDs 42086126
- anticancer activities (Other) — 1 paper: PMIDs 42152582
- cancer immunotherapy (Biological Process) — 1 paper: PMIDs 41866005
- chronic wound (Disease) — 1 paper: PMIDs 42025984
- clinical translation potential (Other) — 1 paper: PMIDs 41857368
- Glyasperin F (Therapy) — 1 paper: PMIDs 42216775
- HIF-1α-SLC7A11 pathway (Pathway) — 1 paper: PMIDs 41990706
- hypoxic-microenvironment-responsive therapeutic strategy (Therapy) — 1 paper: PMIDs 41857368
- LAMA4-integrin-NF-κB axis (Other) — 1 paper: PMIDs 42107509
- liver fibrosis therapy (Therapy) — 1 paper: PMIDs 41819037
- localized therapeutic strategy (Other) — 1 paper: PMIDs 42025984